课题基金 / 基金详情

ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG

ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
癌基因定向合成抗癌药物头孢他汀
批准号:
6750698
负责人:
PHILIP L FUCHS
金额:
$36.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-08-09 至 2005-05-31

项目摘要

项目成果

PHILIP L FUCHS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Principal Investigator's Abstract) This proposal has seven medicinal/biological goals: (1) Synthesize up to seven North 1 and South 1 'slightly simplified' hexacyclic steroidal spiroketal subunits. Convert these materials to South--pyrazine--North trisdecacyclic (thirteen rings) pyrazines using our method for unsymmetrical pyrazine synthesis and compare their anticancer activity to cephalostain 1 (1.2nM avg. NCI panel). (2) Study the contribution of the central arene moiety to anticancer activity by testing pairs of unsymmetrical annulated pyridines derived from the best simplified hexacyclic steroidal subunits. (3) Construct and evaluate one member of a designed new class of inter-phylal agents termed the cephalofurthins to evaluate whether the geranyl geranyl moiety is a recognition element. (4) Prepare and test covalent conjugates of the new agent(s) with folic acid to assay for enhanced (targeted) activity for the treatment of the around 40 percent of cancers which over-express (ten to the 4th power) the folate receptor. (5) Use the biological data from testing of the proposed new materials to complete the mapping of the minimum pharmacophore for the cephalostatin class of antieoplastics. (6) Determine the biological mechanism of action of the trisdecacyclic pyrazines; and (7) Prepare 2-5g of the material which best combines high activity with expedient synthesis to provide a set of new biological tools as well as generating enough agent to initiate clinical trials. Synthesis of the seven hexacyclic spiroketals are projected to require 9-16 operations (compared with 29-31 operations in our 'first generation' synthesis). To accomplish the medicinal/biological goals, efficient new chemistry is required. (A) Utilize a vigorous interactive calculational approach to constantly evaluate synthetic approaches and biological testing data. (B) Test a new siloxysulfonium triflate reagent to effect stereospecific allylic oxidation of a vinyl ether. (C) Investigate the resulting ortho-methylthiophenyldimethylsilyl ether for chemospecific ion-pair self-immolative deprotection. (D) Develop a new annulation of unsymmetrical pyridine rings from 3-ketosteroids via an intramolecular aza-Horner reaction. (E) Generation of the Southern hemispheres requires hydroxylation of the unactivated angular methyl group at the steroidal CD ring junction. This will be accomplished by systematic exploration of the potential of a previously unknown stereospecific dyatropic rearrangement of beta-hydroxyketones and beta-hydroxy lactones to accomplish this transformation.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
A new protocol for in situ dioxirane reactions: stoichiometric in oxone and catalytic in fluorinated acetophenones.
原位二环氧乙烷反应的新方案:臭氧中的化学计量和氟化苯乙酮中的催化。
DOI: 10.1021/ol0348957
发表时间: 2003
期刊: Organic letters.
影响因子: --
作者: [Li,Wei, Fuchs,PhilipL]
通讯作者: Fuchs,PhilipL
Chemistry of trisdecacyclic pyrazine antineoplastics: the cephalostatins and ritterazines.
三十环吡嗪抗肿瘤药的化学:头孢他汀和利特嗪。
DOI: 10.1021/cr800365m
发表时间: 2009-06
期刊: CHEMICAL REVIEWS
影响因子: 62.1
作者: [Lee, Seongmin, LaCour, Thomas G., Fuchs, Philip L.]
通讯作者: Fuchs, Philip L.
Dyotropic rearrangement facilitated proximal functionalization and oxidative removal of angular methyl groups: efficient syntheses of 23'-deoxy cephalostatin 1 analogues.
向变性重排促进了角甲基的近端功能化和氧化去除:23-脱氧头孢他汀 1 类似物的有效合成。
DOI: 10.1021/ja017323v
发表时间: 2002
期刊: Journal of the American Chemical Society
影响因子: 15
作者: [Li,Wei, LaCour,ThomasG, Fuchs,PL]
通讯作者: Fuchs,PL
New oxidative tools for the functionalization of the cephalostatin north 1 hemisphere.
用于头孢他汀北 1 半球功能化的新氧化工具。
DOI: 10.1021/ol034551g
发表时间: 2003
期刊: Organic letters
影响因子: 5.2
作者: [Lee,JongSeok, Fuchs,PhilipL]
通讯作者: Fuchs,PhilipL
10
    ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
    • 批准号:
      6456877
    • 项目类别:
    • 资助金额:
      $6.49万
    • 财政年份:
      1996
    • 负责人:
      PHILIP L FUCHS
    • 依托单位:
    ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
    • 批准号:
      6370491
    • 项目类别:
    • 资助金额:
      $3.16万
    • 财政年份:
      1996
    • 负责人:
      PHILIP L FUCHS
    • 依托单位:
    ONCOGENE-DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
    • 批准号:
      2712677
    • 项目类别:
    • 资助金额:
      $20.13万
    • 财政年份:
      1996
    • 负责人:
      PHILIP L FUCHS
    • 依托单位:
    Synthesis & Mechanism of Cephalostatin Anticancer Drugs
    • 批准号:
      7121185
    • 项目类别:
    • 资助金额:
      $29.24万
    • 财政年份:
      1996
    • 负责人:
      PHILIP L FUCHS
    • 依托单位:
    海外基金